Comparable stake leader
Shay Capital LLC
SEC ownership of Repare Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001808158.
Disclosed value leader
Ansbert Gadicke
Comparable rows
3/16
Latest evidence
20 Jan 2026
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Shay Capital LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
3 of 16
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Shay Capital LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
20 Jan 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001808158
- Issuer location
- Saint Laurent, Quebec, Canada
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Repare Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Shay Capital LLC
Disclosed value leader
Ansbert Gadicke
Comparable rows
3/16
Latest evidence
20 Jan 2026
13D/G
3/4/5
Lead comparable stake: 6.7%
13 rows are not safely comparable across share classes.
13D/G row: Shay Capital LLC
Showing 1-8 of 16 holder rows.
Quick read
Shay Capital LLC leads the comparable SEC ownership view at 6.7%.
3 of 16 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Shay Capital LLC's linked filing trail.
Comparable ownership
Top 3
Shay Capital LLC
6.7%
ARK Investment Management LLC
4.7%
MPM BioVentures 2014, L.P.
4.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 16 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Shay Capital LLC |
13D/G
|
6.7%
|
$7,462,367
2,870,141 shares
|
$0 | 20 Jan 2026 |
| ARK Investment Management LLC |
13D/G
|
4.7%
|
$2,199,996
1,999,996 shares
|
$0 | 31 Dec 2024 |
| MPM BioVentures 2014, L.P. |
13D/G
ANSBERT GADICKE
|
4.6%
|
$2,135,366
1,941,242 shares
|
-$228,990 | 31 Jan 2025 |
| Ansbert Gadicke |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$9,415,026
3,882,485 shares
|
— | 09 Jul 2021 |
| Versant Vantage I, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$560,687
231,211 shares
|
— | 03 Jun 2022 |
| Lloyd Mitchell Segal |
3/4/5
PRESIDENT AND CEO, Director
|
—
mixed-class rows
|
$264,425
468,952 shares
mixed-class rows
|
— | 12 Mar 2025 |
| Maria Koehler |
3/4/5
EVP, CHIEF MEDICAL OFFICER
|
—
class O/S missing
|
$259,707
227,813 shares
|
— | 12 Mar 2025 |
| ORBIMED ADVISORS LLC |
3/4/5
Director
|
—
class O/S missing
|
$233,261
96,190 shares
|
— | 03 Sep 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 20 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to Repare Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
Ansbert Gadicke
Net 12M change
$0
Latest report
28 Jan 2026
Recent insider transactions for Repare Therapeutics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sandra Isabelle Barros Alves | RPTX | Common Shares | Disposed to Issuer | -100% | -31,622 | 0 | 28 Jan 2026 | Direct | ||
| Sandra Isabelle Barros Alves | RPTX | Employee Stock Option (right to buy) | Disposed to Issuer | -100% | -50,500 | 0 | 28 Jan 2026 | Direct | ||
| Steve Forte | RPTX | Common Shares | Disposed to Issuer | -100% | -56,786 | 0 | 28 Jan 2026 | Direct | ||
| Steve Forte | RPTX | Employee Stock Option (right to buy) | Disposed to Issuer | -100% | -1,110,800 | 0 | 28 Jan 2026 | Direct | ||
| Thomas Civik | RPTX | Common Shares | Disposed to Issuer | -100% | -7,500 | 0 | 28 Jan 2026 | Direct | ||
| Carol Schafer | RPTX | Common Shares | Disposed to Issuer | -100% | -8,000 | 0 | 28 Jan 2026 | Direct | ||
| Carol Schafer | RPTX | Stock Option (right to buy) | Disposed to Issuer | -100% | -37,941 | 0 | 28 Jan 2026 | Direct | ||
| Ann D. Rhoads | RPTX | Common Shares | Disposed to Issuer | -100% | -4,000 | 0 | 28 Jan 2026 | Direct | ||
| Bvf Partners L P/Il | RPTX | Common Shares, no par value | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -10,166,943 | 0 | 28 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.